Navin Fluo.Intl. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹42.1K Cr

Growth till FY '28 is largely baked in due to ongoing capex, including new HFC capacity, debottlenecking plant, and Chemours project. Navin Fluorine expects continued strong growth across its business verticals—HPP, Specialty Chemicals, and CDMO—with robust order pipelines and product launches.

From Navin Fluo.Intl.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Price

8,144

Market Cap

₹42.1K Cr

P/E Ratio

52.9

Revenue Rank

Rank 2

Margin Rank

Rank 3

How does Navin Fluo.Intl. rank in Chemicals & Petrochemicals?

Compare Navin Fluo.Intl. against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 2Margin: Rank 3
View Chemicals & Petrochemicals leaderboard →

Navin Fluo.Intl. — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹938 Cr, net profit ₹213 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 2
  • Growth till FY '28 is largely baked in due to ongoing capex, including new HFC capacity, debottlenecking plant, and Chemours project.
  • Advanced materials vertical is being incubated to become a material business unit by the decade's end, focusing on high-growth sectors like data centers, electronics, defense, and semiconductors.
  • Specialty chemicals expected to grow with good order visibility and ramp-up in existing/new molecules, despite pricing pressures, especially in Latin America.
  • CDMO business shows strong momentum with an expanding portfolio of commercial, late-stage, and early-stage programs across therapeutic areas including oncology, respiratory, cardiovascular, neurology, and animal health.
  • New molecule pipeline of 30-40 molecules under active development, with 3-4 molecules expected FDA readouts in 8-12 months.
  • Contractual discussions ongoing for long-term supply agreements (e.g., 35-45% of R32 capacity contracted).
  • Overall, sustainable growth expected fueled by disciplined capex, customer engagement, and product innovation.

📈 Profitability & Margins

Rank 3
  • Navin Fluorine expects continued strong growth across its business verticals—HPP, Specialty Chemicals, and CDMO—with robust order pipelines and product launches.
  • FY '27 growth is backed by ongoing capex (including INR90 crores in advanced materials) leading to capacity expansions and commercial scale-up.
  • EBITDA margins are targeted in the range of 32-33% (+/- 1%) over the next 1-2 years, supported by operating leverage from new capacities.
  • CDMO business anticipates further depth with multiple late-stage FDA readouts over 8-12 months, supporting sustained revenue growth.
  • Advanced materials business aims to become a material business unit by decade-end, contributing accretively to margins and profits.
  • Past capex of INR3,000 crores and upcoming ~INR3,000 crores enable solid growth visibility through FY '28 and beyond, locking in revenue streams and order visibility.
  • Overall, disciplined investments, productivity gains, pricing strategies, and diversified product mix create confidence for sustained earnings expansion and improved EPS.

🏗️ Capital Expenditure Plans

Yes
  • INR 90 crores capex approved for setting up adoption capacities for the advanced materials business, funded through internal accruals. This will cater to indigenous products for emerging sectors like data centers, electronics, defense, and semiconductors. (To be completed by Q2 FY '28)
  • Chemours project as part of advanced materials vertical, targeted for completion by end of Q2 FY '27.
  • Phase 2 cGMP4 capex of INR 125 crores in CDMO business funded through internal accruals, expected operationalization by Q4 FY '27. Part of INR 288 crores cGMP4 capex approved earlier.
  • HFC capacity expansion equivalent to 15,000 metric tons of R32 on track for commissioning in Q3 FY '27.
  • MPP facility debottlenecking at Dahej expected to complete by Q3 FY '27.
  • INR 15.73 crores investment in a 14.9 MW captive hybrid renewable energy project to meet 60%+ of energy needs, supporting sustainability goals.
  • Focus on capital discipline and technology-driven growth with multiple capacity expansions underway.

💰 Fundraising & Capital Structure

No information
  • There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The company highlights that the INR90 crores capex for advanced materials and INR125 crores Phase 2 CDMO capex are being funded through internal accruals.
  • The company has become net debt free during the quarter.
  • Emphasis is on disciplined investment and funding capex via internal accruals rather than external financing.
  • No indications of upcoming equity or debt issuance were discussed in the Q1 FY '27 earnings call.

📋 Order Book & Pipeline

No information
  • Navin Fluorine is actively working on a molecule pipeline of 30 to 40 molecules.
  • About 10 molecules are in the late stage, with 3 to 4 expected to have FDA readouts in the next 8 to 12 months.
  • The company has strong order visibility in the Specialty Chemicals segment with existing and new molecules.
  • CDMO business shows improved visibility with a robust product pipeline and sustained momentum.
  • New capacity for CDMO is dedicated to existing European CDMO partner, with expansion in supply chain participation through MSAs.
  • The company also has upcoming orders related to DRDO, but details remain confidential.
  • Contractual commitments for R32 are in advanced conversations to secure 35%-45% of total capacity over the next five years.
  • Overall, Navin only pursues capex with sufficient revenue visibility and value-accretive opportunities.

Key Metrics

Revenue

Rank 2

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

Frequently Asked Questions

What were Navin Fluo.Intl. Q1 FY27 results?

Growth till FY '28 is largely baked in due to ongoing capex, including new HFC capacity, debottlenecking plant, and Chemours project. Navin Fluorine expects continued strong growth across its business verticals—HPP, Specialty Chemicals, and CDMO—with robust order pipelines and product launches.

What is Navin Fluo.Intl. share price analysis?

Navin Fluo.Intl. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 52.9 with a market cap of ₹42,105 Cr. Investors should review the full earnings analysis for detailed insights.

Is Navin Fluo.Intl. planning capital expenditure?

INR 90 crores capex approved for setting up adoption capacities for the advanced materials business, funded through internal accruals.

Keep Navin Fluo.Intl. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Chemicals & Petrochemicals this season

  • Fineotex Chemical Ltd (Q1 FY27)

    INR 1,000 crores in FY'26. Key concall takeaways from Fineotex Chemical Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Tanfac Inds. (Q1 FY27)

    Around 80% to 85% of the solar grade DHF plant capacity is contracted. Key concall takeaways from Tanfac Inds.'s Q1 FY27 earnings call — and how it ranks…

  • Epigral (Q1 FY27)

    Profit after tax (PAT) grew 25% in Q1 FY27 compared to Q1 FY26, reflecting resilience despite a challenging environment. Key concall takeaways from Epigral's…

  • S H Kelkar & Company Ltd (Q1 FY27)

    15 crore). Key concall takeaways from S H Kelkar & Company Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.